Navigation Links
Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/5/2009

iences, Sigma-Aldrich and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
2. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
3. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
4. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
5. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
6. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
7. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
8. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
9. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
10. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
11. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... VALLEY, Calif. , July 31, 2014 ... San Francisco Bay Area , has acquired ... University of Oxford,s commercialisation company. The potent anti-inflammatory activity ... Greaves at the University of Oxford,s Sir ... The company, which has raised over $1.5 million in ...
(Date:7/31/2014)... DUBLIN , July 31, 2014 ... the "Global Genomics Market 2014-2018" report to ... Genomics is the study of the genetic ... to be a strong basis for the discovery and ... of human diseases or health conditions. Genomics is supported ...
(Date:7/31/2014)... SHENZHEN, China , July 31, 2014 ... purchase of an Irys™System by BGI ... platform to enable comprehensive exploration of human structural variation ... organisms of interest, including those where no reference exists. ... develop new methods for multiplexing on the Irys System, ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Although ... of the first transcriptome-wide analyses appearing around 2008, ... assay for RNA measurement. In the last several ... more specific, work with smaller input amounts, process ... (eg, blood samples). On the bioinformatics side, there ...
Breaking Biology Technology:Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2
... patients with high expression of EpCAM , , ... MITI ), a biopharmaceutical company developing novel, proprietary ... diseases, presented data from a clinical trial investigating its ... chemotherapeutic docetaxel in patients with metastatic breast cancer (MBC) ...
... When he died recently ... lasting impact on both agriculture and weed science around the globe. He devoted his life ... farmers. Thousands of students have followed in his footsteps and are now making their own contribution ... Lawrence, ...
... - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) ... presented during an oral presentation at the American Society ... of April 2009 showed that OGX-427 was well tolerated ... circulating tumor cells at all doses evaluated as well ...
Cached Biology Technology:Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 2Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 3Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 4Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 5Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 2Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 3Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 3OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 5
(Date:7/31/2014)... team of scientists from Spain, France, and the ... that is the oldest definitive member of the ... amber. The discovery and description were made possible ... synchrotron imaging technique, which allows the detailed study ... new species is described in the journal ...
(Date:7/31/2014)... how the brain processes speech, potentially increasing the ... at The University of Texas at Dallas. , ... Ear and Hearing , researchers demonstrated for the ... brain,s recognition of speech sounds. , Noise-induced hearing ... affecting an estimated 15 percent of Americans between ...
(Date:7/31/2014)... Fire was in full fury, raging swiftly from crown ... backcountry of Yosemite National Park in California,s Sierra Nevada ... battle began to turn, enacting a case study in ... fuel large, severe fires. , "When the Rim Fire ... had been used as a management tool, rather than ...
Breaking Biology News(10 mins):UT Dallas study reveals effect of loud noises on brain 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5
... August 30, 2010Anger, depression, and helplessness are the main ... Deepwater Horizon oil spill in the Gulf ... effects, according to an interview in Ecopsychology, a peer-reviewed, ... www.liebertpub.com ). The interview is available free online at ...
... School of Public Health (BUSPH) epidemiologists has found that ... less likely to give birth prematurely. Preterm birth ... -- is the leading cause of infant morbidity and ... unknown, said Rohini Hernandez, the study,s lead author and ...
... in heart muscle cells, which is associated with heart ... to decline, according to a new study by researchers ... A. Carver College of Medicine. The structure is ... membrane called T-tubules. This network is essential for transmitting ...
Cached Biology News:Devastating psychological effects of BP Gulf disaster are explored in Ecopsychology journal 2BUSPH study observes link between decongestant use in pregnant women and lower risk of preterm birth 2Structural defects precede functional decline in heart muscle 2